Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca

Executive Summary

Pfizer, Gilead, Allergan, Valeant and AstraZeneca are among the pharma and biotech companies still to report their third-quarter results. After Merck, Bristol-Myers, Lilly, Amgen, Novartis, Sanofi and others revealed their July-to-September performance, Scrip takes a look at what to expect in the weeks ahead.

Advertisement

Related Content

‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Pfizer Assembling New Commercial Team For Move Into Dermatology
Stronger Together: Pfizer Decides Against A Split
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
J&J's Cash Challenge, Gilead's Life After HCV, Pfizer's Pricing Gripe
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
Allergan Sees Growth From New Launches, Not Big M&A
FDA OK's Gilead's 'TAF' Combo HIV Drug Odefsey

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel